ArticleRespiratory research & clinical practice2026
A multidimensional index with SpO
Article in Respiratory research & clinical practice, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To develop a multidimensional weighted score for progressive fibrotic interstitial lung disease (fILD) on the basis of mortality risk and compare the score with the progressive pulmonary fibrosis (PPF) guideline and Efficacy and Safety of Nintedanib in Patients with Progressive Fibrosing Interstitial Lung Disease (INBUILD) trial criteria. Methods: This was a multicenter retrospective cohort study of fILD patients evaluated from January of 2008 to January of 2020. Disease progression was evaluated by changes in dyspnea, HRCT findings, FVC, DL Results: A total of 380 patients were evaluated. Cox regression was used in order to assign points to the progression criteria: a decrease of < 90% in SpO Conclusions: A multidimensional weighted score allows us to estimate the risk of progressive fILD. When dichotomized, the concordance with the PPF guideline and INBUILD trial criteria is high. External validation is required before routine clinical application.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.